Imipenem/Cilastatine Tamrisa

Imipenem, the active ingredient in Imipenem/Cilastatin Tamrisa, is a carbapenem antibiotic presented as an injection for intravenous infusion use. It treats serious bacterial infections such as complicated intra‑abdominal infections, urinary tract infections, skin and soft‑tissue infections, hospital‑acquired pneumonia, febrile neutropenia and sepsis in hospitalized patients.

GNH USA supplies Imipenem/Cilastatin Tamrisa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Imipenem/cilastatin is a carbapenem antibiotic used for serious bacterial infections affecting various organ systems.

- Complicated intra‑abdominal infections: provides broad‑spectrum bacterial eradication in the abdominal cavity. - Complicated urinary tract infections: achieves bacterial clearance in the urinary tract. - Skin and soft‑tissue infections: treats severe cellulitis and wound infections. - Hospital‑acquired and ventilator‑associated pneumonia: combats resistant pathogens in the lungs. - Febrile neutropenia: offers rapid infection control in neutropenic patients. - Sepsis: contributes to systemic infection management.

Adverse reactions may occur with any intravenous antibiotic and should be monitored.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Vomiting: occasional emesis following infusion. - Diarrhea: loose stools, may be self‑limiting. - Headache: transient cranial discomfort. - Infusion site phlebitis: redness or pain at the catheter site. - Elevated liver enzymes: mild transaminase increase.

Serious or Rare Side Effects: - Seizures: risk heightened in patients with CNS disorders or renal impairment. - Anaphylaxis: severe allergic reaction requiring immediate intervention. - Clostridioides difficile‑associated diarrhea: potentially life‑threatening colitis. - Renal impairment: worsening kidney function in susceptible individuals. - Thrombocytopenia: reduced platelet count, may cause bleeding. - Neutropenia: decreased neutrophil count, increasing infection risk.

Careful assessment and monitoring are required before and during therapy. - Assess renal function: adjust dosing in patients with impaired clearance. - Monitor for seizures: heightened risk in those with CNS disease or high doses. - Evaluate liver enzymes: watch for hepatic toxicity during prolonged use. - Review concomitant antibiotics: avoid overlapping toxicities and antagonism. - Check allergy history: contraindicated in patients with known carbapenem hypersensitivity. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Imipenem/cilastatin may interact with several agents; clinical judgment is essential.

Major Interactions (Avoid): - Valproic acid: reduces serum levels, risking loss of seizure control. - Other carbapenems: additive toxicity, especially neurotoxicity. - Probenecid: may increase plasma concentrations, enhancing adverse effects.

Moderate Interactions (Monitor Closely): - Aminoglycosides: combined nephrotoxic potential, monitor renal function. - Loop diuretics: may exacerbate renal impairment, adjust dosing as needed. - Anticoagulants (e.g., warfarin): possible alteration of INR, check coagulation parameters.